What helps, what fails, and how well anything is evidenced

Antihistamines: unreliable, not useless

Antihistamines are the reasonable first thing to try, and in aquagenic pruritus they often disappoint. A documented case of primary aquagenic pruritus was refractory to five years of H1 and H2 blockade; another failed high-dose fexofenadine at 360 mg twice daily and then omalizumab at 300 mg every four weeks.¹

It would be easy to overstate this, so: other reviews report histamine antagonists helping around half of the patients who were actually treated, and in the 102-patient polycythaemia vera cohort only three people received any antipruritic treatment at all — far too few to conclude anything from.² The defensible claim is that antihistamines are unreliable here and that failure is common, not that they never work.

That still matters practically. If antihistamines have failed you, that is a recognised feature of the condition rather than evidence that the itch is imaginary or that you are exaggerating — and it is a reason to discuss other mechanisms instead of escalating the dose indefinitely.

Things people manage themselves

• Bathing temperature sequence. Starting very hot and finishing cooler is a widely reported personal strategy. The evidence cuts both ways: in one polycythaemia vera cohort hot water aggravated the itch in 57.1% of patients against 1.9% for cold. Test it on yourself; do not assume.
• Rapid, complete drying. Microfibre towels or warm air, promptly. One of the most consistently reported self-management steps.
• Sodium bicarbonate baths. 25 g to 200 g of bicarbonate raises bath water pH to about 8–9, and this is described in the literature as highly effective in classic primary aquagenic pruritus, as well as safe and cheap. Individual results vary widely — some accounts report no benefit whatsoever.
• Shorter exposure and trigger notes. Less time under running water, and a written record of trigger, latency, duration and sites. The notes are what make the next appointment productive.

Moisturisers deserve a specific mention because they are what everyone is told to use. They treat dry skin, which is a genuinely common cause of post-shower itching and worth excluding. They do not appear to touch aquagenic pruritus itself.

Beta-alanine: the interesting lead

β-alanine is an amino acid sold as a sports supplement, and it is the most intriguing thing in this field — because it works in the opposite direction to intuition. It is an agonist at MrgprD, the receptor implicated in non-histaminergic itch. Taking it before water contact appears to pre-activate and then desensitise the C-fibres that water would otherwise excite. Proposed secondary effects include enhanced glutamate release suppressing mast-cell activation, and conversion to carnosine, which buffers pH and stabilises mast-cell membranes.

What the evidence actually consists of:

Reported dosing runs from under 2 g up to the 4–5 g dissolved in water 5 to 15 minutes before showering used in the case report. In the survey, 73.6% took it only as needed and 90% reported the benefit holding up over time rather than fading.³

Be clear about what this evidence is, though. There is no randomised controlled trial. One arm of it is 75 self-selected people, predominantly Italian, recruited through a social-media group for the condition — a group already inclined to report what worked for them. The other is a single patient. That is enough to make β-alanine worth discussing with a clinician; it is not enough to call it established.

Options a clinician may consider

These are prescription-only, and the ones aimed at myeloproliferative disease are specialist haematology decisions made about the underlying condition, not about the itch alone.

Two things are worth drawing out of that table. First, no complete hematological response guaranteed relief — the cohort found no correlation between controlling the blood counts and the itch resolving.⁴ Second, the treatments with the strongest numbers behind them are treatments for an underlying blood disorder, which is the practical argument for establishing whether you have one.

References

Each figure on this page links to the study it came from, with the sample size shown so you can weigh it yourself. Where a claim rests on a single case report or a self-selected survey, it says so.

1. Alinaghi F, Elberling J. Primary aquagenic pruritus successfully treated by β-alanine: a case report. Case Reports in Dermatology 2025;17:252–4. doi:10.1159/000545842 Single case report (n=1); benefit held at 20-week follow-up doi.org ↩
2. Aquagenic pruritus in polycythemia vera: clinical characteristics. Acta Dermato-Venereologica. doi:10.2340/00015555-2906 102 patients; only 3 received any antipruritic treatment medicaljournals.se ↩
3. Beta-alanine as a potential treatment for aquagenic pruritus: an online social media-based survey study. PubMed 40657651 75 self-reported patients recruited via a social-media group — self-selected, not a trial pubmed.ncbi.nlm.nih.gov ↩
4. Ruxolitinib and hydroxycarbamide are the most efficient drugs to reduce aquagenic pruritus intensity in a real-world cohort of patients with myeloproliferative neoplasms. OBENE Observatory (NCT02897297). PMC12698927 489 patients — the largest treatment dataset on this page pmc.ncbi.nlm.nih.gov ↩
5. Landtblom AR, et al. Omalizumab alleviates pruritus in myeloproliferative neoplasms. Haematologica 2023. doi:10.3324/haematol.2022.281639. PMC10316269 Small case series; median treatment 13 months pmc.ncbi.nlm.nih.gov ↩
6. Koumaki D, et al. Omalizumab for the management of refractory aquagenic pruritus. Journal of the European Academy of Dermatology and Venereology 2023. doi:10.1111/jdv.19306 onlinelibrary.wiley.com ↩
7. Beta-alanine and aquagenic pruritus: proposed neuroimmune mechanism. JMIR Dermatology 2026;1:e90737. PMID 41880222 Mechanistic viewpoint, not a trial derma.jmir.org ↩